189 related articles for article (PubMed ID: 2510972)
1. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
Cryz SJ; Sadoff JC; Que JU
Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
[No Abstract] [Full Text] [Related]
2. Immunologic considerations for the development of conjugate vaccines.
Garner CV; Pier GB
Contrib Microbiol Immunol; 1989; 10():11-7. PubMed ID: 2510971
[No Abstract] [Full Text] [Related]
3. Contemporary trends in conjugate vaccine development.
Cruse JM; Lewis RE
Contrib Microbiol Immunol; 1989; 10():1-10. PubMed ID: 2510970
[No Abstract] [Full Text] [Related]
4. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
Sourek J; Výmola F; Zelenková L
Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
[TBL] [Abstract][Full Text] [Related]
6. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
Joó I; Stanislavskii ES
J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
[TBL] [Abstract][Full Text] [Related]
7. The cellular basis of the immune response to conjugate vaccines.
Bixler GS; Pillai S
Contrib Microbiol Immunol; 1989; 10():18-47. PubMed ID: 2684506
[No Abstract] [Full Text] [Related]
8. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
9. [Pseudomonas aeruginosa preparations for active immunization].
Nazarchuk LV
Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
[No Abstract] [Full Text] [Related]
10. Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers.
Anderson PW; Stein EC; Insel RA
Contrib Microbiol Immunol; 1989; 10():115-24. PubMed ID: 2684504
[No Abstract] [Full Text] [Related]
11. Recent trends in the developments of bacterial vaccines.
Lindberg AA; Pillai S
Dev Biol Stand; 1996; 87():59-71. PubMed ID: 8854003
[No Abstract] [Full Text] [Related]
12. Effectiveness of immunization with single and multi-component vaccines prepared from a common antigen (OEP), protease and elastase toxoids of Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink due to P. aeruginosa.
Homma JY; Abe C; Tanamoto K; Hirao Y; Morihara K; Tsuzuki H; Yanagawa R; Honda E; Aoi Y; Fujimoto Y; Goryo M; Imazeki N; Noda H; Goda A; Takeuchi S; Ishihara T
Jpn J Exp Med; 1978 Apr; 48(2):111-33. PubMed ID: 101698
[TBL] [Abstract][Full Text] [Related]
13. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
[TBL] [Abstract][Full Text] [Related]
14. A new polyvalent pseudomonas vaccine.
Merle P; Robbel L; Hungerer KD
Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
[TBL] [Abstract][Full Text] [Related]
15. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
[TBL] [Abstract][Full Text] [Related]
16. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections.
Sourek J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656
[TBL] [Abstract][Full Text] [Related]
17. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
Schiller B; Lysakowska E; Owczarska K
Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
[No Abstract] [Full Text] [Related]
18. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
Cryz SJ; Sadoff JC; Fürer E; Germanier R
J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
[TBL] [Abstract][Full Text] [Related]
19. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
[No Abstract] [Full Text] [Related]
20. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides.
Schreiber JR; Dahlhauser P
Infect Immun; 1994 Jan; 62(1):308-12. PubMed ID: 8262644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
